Aprea Therapeutics Inc (APRE)
NASDAQ:APRE
Total Valuation
Aprea Therapeutics has a market cap or net worth of $8.41M. The enterprise value is -$9.83M.
Market Cap$8.41M
Enterprise Value-$9.83M
Share Statistics
Aprea Therapeutics has 11,452,452 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding11,452,452
Owned by Insiders6.54%
Owned by Institutions11.42%
Financial Efficiency
Aprea Therapeutics’s return on equity (ROE) is -1.01 and return on invested capital (ROIC) is -100.49%.
Return on Equity (ROE)-1.01
Return on Assets (ROA)-0.79
Return on Invested Capital (ROIC)-100.49%
Return on Capital Employed (ROCE)-1.00
Revenue Per Employee35.72K
Profits Per Employee-1.57M
Employee Count8
Asset Turnover0.02
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Aprea Therapeutics is ―. Aprea Therapeutics’s PEG ratio is 0.02.
PE Ratio―
PS Ratio19.52
PB Ratio0.42
Price to Fair Value0.42
Price to FCF-0.43
Price to Operating Cash Flow-0.43
PEG Ratio0.02
Income Statement
In the last 12 months, Aprea Therapeutics had revenue of 285.76K and earned -12.60M in profits. Earnings per share was -1.93.
Revenue285.76K
Gross Profit264.04K
Operating Income-13.23M
Pretax Income-12.60M
Net Income-12.60M
EBITDA-13.23M
Earnings Per Share (EPS)-1.93
Cash Flow
In the last 12 months, operating cash flow was -13.09M and capital expenditures 0.00, giving a free cash flow of -13.09M billion.
Operating Cash Flow-13.09M
Free Cash Flow-13.09M
Free Cash Flow per Share-1.14
Dividends & Yields
Aprea Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.85
52-Week Price Change-52.65%
50-Day Moving Average0.74
200-Day Moving Average1.22
Relative Strength Index (RSI)48.66
Average Volume (3m)55.77K
Important Dates
Aprea Therapeutics upcoming earnings date is May 18, 2026, After Close (Confirmed).
Last Earnings DateMar 16, 2026
Next Earnings DateMay 18, 2026
Ex-Dividend Date―
Financial Position
Aprea Therapeutics as a current ratio of 5.63, with Debt / Equity ratio of 0.00%
Current Ratio5.63
Quick Ratio5.63
Debt to Market Cap0.00
Net Debt to EBITDA1.10
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Aprea Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Aprea Therapeutics EV to EBITDA ratio is 0.68, with an EV/FCF ratio of 0.70.
EV to Sales-31.57
EV to EBITDA0.68
EV to Free Cash Flow0.70
EV to Operating Cash Flow0.70
Balance Sheet
Aprea Therapeutics has $14.60M in cash and marketable securities with $0.00 in debt, giving a net cash position of $14.60M billion.
Cash & Marketable Securities$14.60M
Total Debt$0.00
Net Cash$14.60M
Net Cash Per Share$1.27
Tangible Book Value Per Share$1.90
Margins
Gross margin is 92.40%, with operating margin of -4631.12%, and net profit margin of -4409.16%.
Gross Margin92.40%
Operating Margin-4631.12%
Pretax Margin-4409.16%
Net Profit Margin-4409.16%
EBITDA Margin-4631.12%
EBIT Margin-4631.12%
Analyst Forecast
The average price target for Aprea Therapeutics is $4.40, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$4.40
Price Target Upside502.74% Upside
Analyst ConsensusStrong Buy
Analyst Count3
Revenue Growth Forecast-62.75%
EPS Growth Forecast23.87%